The headline EPS result misses consensus, but it is almost entirely an accounting swing rather than higher operating burn. The published consensus called for a loss of about $0.39 per share; reported loss was $1.88 per share. However, a $205.6 million non-cash loss from revaluing warrants accounted for roughly $1.52 per share of that gap. Excluding that share-price-linked item, the implied loss was about $0.36 per share—modestly better than consensus. The meaningful operating read is that quarterly R&D fell year over year while G&A rose for launch preparation, leaving operating expenses up a more manageable 22% to $52.4 million (Statements of Operations; Research and development expenses).
| Metric | Q2 2026 | Q2 2025 | Expectation / read |
|---|---|---|---|
| Reported net loss per share | $(1.88) | $(0.41) | Worse than published consensus of about $(0.39), driven by warrant revaluation (Statements of Operations) |
| Warrant fair-value loss | $(205.6)m | $(2.5)m | Non-cash item; explains most of the reported EPS miss (Statements of Operations) |
| Implied loss per share excluding warrant revaluation | ~$(0.36) | — | Modestly better than the published consensus of about $(0.39), calculated from filing figures |
| Operating expenses | $52.4m | $42.9m | Higher, as commercial-readiness spending ramps (Statements of Operations) |
| R&D expense | $29.2m | $30.3m | Lower as the TRD Phase 3 program nears completion (Research and development expenses) |
| G&A expense | $23.2m | $12.6m | Sharply higher due to launch-preparation activity (General and administrative expenses) |
| Cash and cash equivalents | $433.3m | $149.6m at Dec. 31, 2025 | Large cash balance, though no fresh runway guidance was provided here (Balance Sheet) |
The clinical and regulatory update clears an expected milestone rather than advancing the timetable. Management says the second Phase 3 study now shows durable benefit through six months, which supports the COMP360 case and resolves the previously pending longer-term readout. But the filing does not provide detailed efficacy or safety tables, so investors cannot independently assess the magnitude or trade-offs of that durability claim from this release alone (Business Highlights). More importantly, the final NDA submission remains targeted for Q4 2026 and a potential commercial launch remains first half of 2027, subject to FDA approval and DEA rescheduling—both consistent with the standing plan rather than an acceleration (Business Highlights).
Cash is substantial, but commercialization is becoming the main cost driver. Cash and equivalents stood at $433.3 million, while R&D declined as pivotal trial costs eased. That supports execution into the regulatory period. The offset is G&A nearly doubling year over year as Compass builds launch capabilities before approval; the company is deliberately shifting from a trial-focused cost base toward a commercial one before it has product revenue (Balance Sheet; General and administrative expenses).
Net: modestly better underlying quarterly economics and a delivered durability update outweigh the mechanical EPS miss, but there is no new timing catalyst. The result is more constructive than the $1.88 headline loss suggests, yet the key approval, rescheduling, and launch milestones remain conditional and unchanged.
Read the original 8-K on SEC EDGAR ↗